Treats osteoarthritis or rheumatoid arthritis. ANDA 203995, held by Amneal Pharmaceuticals. Diclofenac Sodium; Misoprostol.
As of Nov 21, 2026, ANDA 203995 (Diclofenac Sodium and Misoprostol), held by Amneal Pharmaceuticals, was first approved by FDA on Nov 25, 2016, with 6 approved supplements and 0 published complete response letters.
Diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in adult patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications. For a list of factors that may increase the risk of NSAID-induced gastric and duodenal ulcers and their complications.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 25, 2016 | Original application | Approved | None posted |
| Diclofenac Sodium and Misoprostol50MG;0.2MG · tablet, delayed release;oral | Diclofenac Sodium; Misoprostol | Rx |
| Diclofenac Sodium and Misoprostol75MG;0.2MG · tablet, delayed release;oral | Diclofenac Sodium; Misoprostol | Rx |
| Mar 31, 2025 | Supplement 24Labeling · Standard review | Approved | None posted |
| Mar 31, 2025 | Supplement 18Labeling · Standard review | Approved | None posted |
| Mar 31, 2025 | Supplement 15Labeling · Standard review | Approved | None posted |
| Mar 31, 2025 | Supplement 14Labeling · Standard review | Approved | None posted |
| Mar 31, 2025 | Supplement 13Labeling · Standard review | Approved | None posted |
| Mar 31, 2025 | Supplement 11Labeling · Standard review | Approved | None posted |
| Nov 25, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters